| Literature DB >> 22180731 |
Saul N Rajak1, Esmael Habtamu, Helen A Weiss, Amir Bedri Kello, Teshome Gebre, Asrat Genet, Robin L Bailey, David C W Mabey, Peng T Khaw, Clare E Gilbert, Paul M Emerson, Matthew J Burton.
Abstract
BACKGROUND: Trachomatous trichiasis can cause corneal damage and visual impairment. WHO recommends surgery for all cases. However, in many regions surgical provision is inadequate and patients frequently decline. Self-epilation is common and was associated with comparable outcomes to surgery in nonrandomised studies for minor trichiasis (<six lashes touching eye). This trial investigated whether epilation is noninferior to surgery for managing minor trichiasis. METHODS ANDEntities:
Mesh:
Year: 2011 PMID: 22180731 PMCID: PMC3236738 DOI: 10.1371/journal.pmed.1001136
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Figure 1Trial profile.
Baseline demographic and clinical characteristics of participants in each arm of the trial.
| Characteristic | Surgery, | Epilation, | ||
|
| Percent or 95% CI |
| Percent or 95% CI | |
|
| 448 | (68.9%) | 415 | (63.9%) |
|
| ||||
| 18–30 | 69 | (10.6%) | 67 | (10.3%) |
| 30–39 | 113 | (17.4%) | 108 | (16.6%) |
| 40–49 | 156 | (24.0%) | 150 | (23.1%) |
| 50–59 | 160 | (24.6%) | 158 | (24.3%) |
| 60–69 | 112 | (17.2%) | 122 | (18.8%) |
| 70+ | 40 | (6.2%) | 45 | (6.9%) |
| Mean (SD, 95% CI) | 49.9 | (14.4, 48.8–51.0) | 50.7 | (14.5, 49.6–51.8) |
|
| 581 | (89.4%) | 588 | (90.5) |
|
| 19.9 | (2.3, 19.7–20.1) | 20.0 | (2.4, 19.8–20.2) |
|
| 319 | (49.1%) | 302 | (46.5%) |
|
| ||||
| −0.2 to 0.3 | 243 | (37.7%) | 211 | (32.5%) |
| 0.3–0.7 | 261 | (40.5%) | 264 | (40.7%) |
| 0.7–1.1 | 83 | (12.9%) | 89 | (13.7%) |
| 1.1–2.0 | 19 | (3.0%) | 28 | (4.3%) |
| CF/HM/PL | 30 | (4.7%) | 51 | (7.9%) |
| NPL | 9 | (1.4%) | 6 | (0.9%) |
| Not measurable | 5 | (0.8%) | 1 | (0.2%) |
|
| ||||
| 0 | 276 | (42.5%) | 292 | (44.9%) |
| 1 | 258 | (39.7%) | 254 | (39.1%) |
| 2 | 113 | (17.4%) | 102 | (15.7%) |
| 3 | 3 | (0.5%) | 2 | (0.3%) |
| 4 | 0 | (0.0%) | 0 | (0.0%) |
|
| ||||
| Mean (95% CI) | 1.52 | (1.43–1.62) | 1.62 | (1.52–1.72) |
| None, epilating | 124 | (19.1%) | 113 | (17.4%) |
| 1–5 lashes | 526 | (80.9%) | 537 | (82.6%) |
|
| ||||
| Corneal ± peripheral | 462 | (71.1%) | 470 | (72.3%) |
| Peripheral only | 188 | (28.9%) | 180 | (27.7%) |
|
| 70 | (10.8%) | 57 | (8.8%) |
|
| ||||
| CC0, none | 345 | (53.1%) | 330 | (50.8%) |
| CC1, peripheral | 168 | (25.9%) | 145 | (22.3%) |
| CC2a, off centre faint | 76 | (11.7%) | 97 | (14.9%) |
| CC2b, off centre dense | 9 | (1.4%) | 15 | (2.3%) |
| CC2c, central faint | 30 | (4.6%) | 43 | (6.6%) |
| CC2d, central dense | 11 | (1.7%) | 14 | (2.2%) |
| CC3, total central dense | 10 | (1.5%) | 4 | (0.6%) |
| CC4, phthisis | 1 | (0.2%) | 2 | (0.3%) |
| CO or CC2/CC3 | 137 | (21.1%) | 175 | (26.9%) |
|
| ||||
| None (P0) | 52 | (8.0%) | 66 | (10.2%) |
| Mild (P1) | 248 | (38.2%) | 248 | (38.1%) |
| Moderate (P2) | 297 | (45.7%) | 282 | (43.4%) |
| Severe (P3) | 53 | (8.1%) | 54 | (8.3%) |
|
| ||||
| None (C0) | 3 | (0.5%) | 4 | (0.6%) |
| Mild (C1) | 60 | (9.2%) | 52 | (8.0%) |
| Moderate (C2) | 508 | (78.2%) | 520 | (80.0%) |
| Severe (C3) | 79 | (12.2%) | 74 | (11.4%) |
|
| ||||
| 0 | 7 | (1.1%) | 5 | (0.8%) |
| 1 | 18 | (2.8%) | 25 | (3.9%) |
| 2 | 165 | (25.4%) | 146 | (22.5%) |
| 3 | 460 | (70.8%) | 474 | (72.9%) |
|
| 10 | (1.5%) | 9 | (1.4%) |
|
| ||||
| 0 | 9 | (1.4%) | 13 | (2.0%) |
| 1 | 10 | (1.5%) | 13 | (2.0%) |
| 2 | 12 | (1.9%) | 28 | (4.3%) |
| 3 | 43 | (6.6%) | 79 | (12.2%) |
| 4 | 576 | (88.6%) | 517 | (79.5%) |
Participants with bilateral TT had one eye randomly selected as the trial eye.
Unable to cooperate with visual acuity measurement.
BMI, body mass index; CF, count fingers; HM, hand movements; PL, perception of light; NPL, no perception of light; SD, standard deviation; VA, visual acuity.
Figure 2Kaplan Meier graph of time to failure.
Clinical characteristics of participants in each arm of the trial at 12 and 24 mo.
| Characteristic | 12 mo | 24 mo | ||||||
| Surgery, | Epilation, | Surgery, | Epilation, | |||||
|
| 0.11 | (0.07–0.14) | 1.00 | (0.89–1.11) | 0.09 | (0.06–0.12) | 0.95 | (0.84–1.06) |
|
| ||||||||
| −0.2 to 0.3 | 225 | (36.4%) | 189 | (31.8%) | 200 | (32.7%) | 167 | (27.8%) |
| 0.3–0.7 | 261 | (42.2%) | 231 | (38.8%) | 272 | (44.4%) | 258 | (43.0%) |
| 0.7–1.1 | 72 | (11.6%) | 95 | (16.0%) | 79 | (12.9%) | 93 | (15.5%) |
| 1.1–2.0 | 26 | (4.2%) | 33 | (5.6%) | 25 | (4.1%) | 34 | (5.7%) |
| CF/HM/PL | 30 | (4.9%) | 37 | (6.2%) | 28 | (4.6%) | 40 | (6.7%) |
| NPL | 5 | (0.8%) | 10 | (1.7%) | 8 | (1.3%) | 8 | (1.3%) |
|
| ||||||||
| >0.3 worse | 49 | (8.0%) | 66 | (11.1%) | 71 | (11.7%) | 87 | (14.5%) |
| 0.1–0.3 worse | 119 | (19.3%) | 108 | (18.2%) | 136 | (22.4%) | 137 | (22.9%) |
| Within 0.1 (same) | 308 | (50.0%) | 293 | (49.3%) | 277 | (45.6%) | 261 | (43.6%) |
| 0.1–0.3 better | 97 | (15.8%) | 97 | (16.3%) | 85 | (14.0%) | 75 | (12.5%) |
| >0.3 better | 43 | (7.0%) | 30 | (5.1%) | 38 | (6.3%) | 39 | (6.5%) |
|
| ||||||||
| 0 | 598 | (96.5%) | 223 | (37.3%) | 588 | (95.9%) | 167 | (27.7%) |
| 1 | 19 | (3.1%) | 219 | (36.6%) | 18 | (2.9%) | 162 | (26.9%) |
| 2 | 3 | (0.5%) | 154 | (25.8%) | 7 | (1.1%) | 272 | (45.1%) |
| 3 | 0 | (0.0%) | 2 | (0.3%) | 0 | (0.0%) | 2 | (0.3%) |
| 4 | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) |
|
| ||||||||
| CC0, none | 344 | (55.5%) | 275 | (46.0%) | 354 | (57.8%) | 290 | (48.1%) |
| CC1, peripheral | 151 | (24.4%) | 147 | (24.6%) | 136 | (22.2%) | 140 | (23.2%) |
| CC2a, off centre faint | 70 | (11.3%) | 102 | (17.1%) | 67 | (10.9%) | 98 | (16.3%) |
| CC2b, off centre dense | 14 | (2.3%) | 18 | (3.0%) | 15 | (2.5%) | 25 | (4.2%) |
| CC2c, central faint | 22 | (3.6%) | 35 | (5.9%) | 18 | (2.9%) | 28 | (4.6%) |
| CC2d, central dense | 12 | (1.9%) | 16 | (2.7%) | 15 | (2.5%) | 14 | (2.3%) |
| CC3, total central dense | 6 | (1.0%) | 2 | (0.3%) | 7 | (1.1%) | 5 | (0.8%) |
| CC4, phthisis | 1 | (0.2%) | 3 | (0.5%) | 1 | (0.2%) | 3 | (0.5%) |
|
| ||||||||
| More corneal opacity | 7 | (1.1%) | 12 | (2.0%) | 25 | (4.1%) | 33 | (5.5%) |
| No change | 602 | (97.3%) | 575 | (96.8%) | 579 | 94.6%) | 561 | (93.3%) |
| Less corneal opacity | 10 | (1.6%) | 7 | (1.2%) | 8 | (1.3%) | 7 | (1.2%) |
|
| ||||||||
| >3 grades worse | 1 | (0.2%) | 2 | (0.3%) | 1 | (0.2%) | 1 | (0.2%) |
| 3 grades worse | 0 | (0.0%) | 0 | (0.0%) | 1 | (0.2%) | 1 | (0.2%) |
| 2 grades worse | 17 | (2.9%) | 27 | (4.5%) | 18 | (2.9%) | 22 | (3.7%) |
| 1 grade worse | 61 | (9.8%) | 75 | (12.5%) | 44 | (7.2%) | 77 | (12.8%) |
| No change | 452 | (72.9%) | 418 | (69.9%) | 457 | (74.6%) | 436 | (72.3%) |
| 1 grade better | 72 | (11.6%) | 50 | (8.4%) | 71 | (11.6%) | 44 | (7.3%) |
| 2 grades better | 16 | (2.6%) | 23 | (3.9%) | 19 | (3.1%) | 19 | (3.2%) |
| 3 grades better | 1 | (0.2%) | 3 | (0.5%) | 1 | (0.2%) | 3 | (0.5%) |
| >3 grades better | 0 | (0.0%) | 0 | (0.0%) | 1 | (0.2%) | 0 | (0.0%) |
|
| ||||||||
| None (P0) | 172 | (27.7%) | 137 | (22.9%) | 328 | (53.5%) | 269 | (44.6%) |
| Mild (P1) | 279 | (45.0%) | 251 | (42.0%) | 130 | (21.2%) | 130 | (21.6%) |
| Moderate (P2) | 163 | (26.3%) | 191 | (31.9%) | 147 | (24.0%) | 186 | (30.9%) |
| Severe (P3) | 6 | (1.0%) | 19 | (3.2%) | 8 | (1.3%) | 18 | (3.0%) |
|
| ||||||||
| 0 | 115 | (18.6%) | 7 | (1.2%) | 4 | (12.1%) | 5 | (0.8%) |
| 1 | 88 | (14.2%) | 9 | (1.5%) | 63 | (10.3%) | 6 | (1.0%) |
| 2 | 258 | (41.6%) | 83 | (13.9%) | 309 | (50.4%) | 54 | (9.0%) |
| 3 | 159 | (25.7%) | 499 | (83.4%) | 167 | (27.2%) | 537 | (89.2%) |
|
| 9 | (1.45%) | 11 | (1.8%) | 2 | (0.3%) | 1 | (0.2%) |
CF, count fingers; HM, hand movements; PL, perception of light; NPL, no perception of light; VA, visual acuity.
Univariable and multivariable associations for reaching endpoint in the epilation group.
| Variable | OR | 95% CI |
|
|
| |||
| No lashes at baseline (successful epilation) | 0.27 | 0.11–0.68 | 0.005 |
| Entropion (>grade 1) at baseline | 1.75 | 1.08–2.83 | 0.02 |
| Conjunctivalisation | 1.51 | 0.97–2.33 | 0.07 |
| Conjunctival bacteria at baseline | 1.00 | 0.51–1.98 | 0.99 |
| Persistent inflammation (grade 3+ for 3+ examinations) | 1.70 | 1.08–2.67 | 0.02 |
| Female | 0.96 | 0.60–1.55 | 0.88 |
| Age<30 y | 2.38 | 1.28–4.40 | 0.006 |
| Literate | 1.52 | 0.76–3.05 | 0.24 |
| BMI<18 | 1.48 | 0.86–2.54 | 0.15 |
|
| |||
| No lashes at baseline (successful epilation) | 0.33 | 0.13–0.86 | 0.02 |
| Entropion (>grade 1) at baseline | 1.72 | 0.98–3.02 | 0.06 |
| Conjunctivalisation | 1.68 | 0.94–3.00 | 0.08 |
| Persistent inflammation (grade 3+ for 3+ examinations) | 1.52 | 0.90–2.57 | 0.12 |
| Age<30 y | 2.00 | 0.91–4.39 | 0.09 |
| BMI<18 | 1.47 | 0.79–2.75 | 0.22 |
Likelihood ratio test, no evidence of nonlinearity. Therefore combined measure of conjunctivilisation used in logistic regression model.
BMI, body mass index.
Postsurgical complications (a) at 7–10-d follow-up and (b) at any subsequent follow-up.
| Outcome |
| |
|
| ||
| Undercorrection (lashes touching or nearly touching globe) | 5 | (0.8%) |
| Overcorrection | 2 | (0.3%) |
| Infection/red eye | 3 | (0.5%) |
| Infection and undercorrection | 1 | (0.2%) |
| Bleeding | 3 | (0.5%) |
|
| ||
| Recurrence | 105 | (16.2%) |
| Granuloma | 18 | (2.9%) |
| Notching | 29 | (4.7%) |
Symptoms reported by participants at 12- and 24-mo follow-ups.
| Characteristic | 12 mo | 24 mo | ||||||
| Surgery, | Epilation, | Surgery, | Epilation, | |||||
| Vision | ||||||||
| Better | 484 | (78.2%) | 200 | (33.4%) | 545 | (88.9%) | 153 | (25.4%) |
| Same | 87 | (14.0%) | 297 | (49.7%) | 59 | (9.6%) | 446 | (74.1%) |
| Worse | 48 | (7.8%) | 101 | (16.9%) | 9 | (1.5%) | 3 | (0.5%) |
| Eye pain | 272 | (44.0%) | 417 | (69.7%) | 353 | (57.6%) | 498 | (82.6%) |
| Eye watering | 318 | (51.4%) | 378 | (63.2%) | 366 | (59.7%) | 423 | (70.2%) |
| Dry eye | 138 | (22.3%) | 162 | (27.1%) | 134 | (21.9%) | 167 | (27.7%) |
| Treatment pain | ||||||||
| None | 49 | (8.0%) | 167 | (33.3%) | — | — | ||
| Mild | 274 | (44.8%) | 193 | (38.5%) | — | — | ||
| Moderate | 17 | (2.8%) | 6 | (1.2%) | — | — | ||
| Severe | 262 | (42.8%) | 136 | (27.1%) | — | — | ||
| Don't remember | 10 | (1.6%) | 0 | (0.0%) | — | — | ||
As recalled at 12 mo.